Aurigene and Pcovery in pact to undertake anti-fungal drug discovery

Views: 644

eHEALTH Bureau Aurigene Discovery Technologies Ltd, a collaborative drug discovery company with a proven track record of successful partnerships with about 10 collaborators globally, has announced a drug discovery deal with Danish start-up Pcovery, which designs and develops original drugs and agrochemicals. Under the terms of this agreement, Aurigene and Pcovery will work collaboratively to progress early hits available with Pcovery through the drug discovery cycle up to IND submission for anti-fungal indications. Aurigene will support Pcovery through its structure based discovery approaches and medicinal chemistry expertise to advance the early hits from Pcovery. Financial details of the deal have not been disclosed.Commenting on the deal CSN Murthy, CEO, Aurigene said, “This deal demonstrates Aurigene’s pioneering position in undertaking collaborative drug discovery projects and also strengthens Aurigene’s presence in the anti-infectives space.” Commenting on the deal Dr Morten Jeppe Buch Pedersen, CEO, Pcovery said, “We believe that this agreement represents a most significant move for Pcovery. The combination of Aurigene and Pcovery, and of our shared knowledge and technology, should allow us to be able to bring innovative medicine to patients.”

Most Popular

To Top